) --




) hit a new 52-week low Friday as it is currently trading at $1.01, below its previous 52-week low of $2.71 with 54,933 shares traded as of 9:30 a.m. ET. Average volume has been 789,400 shares over the past 30 days.

China-biotics has a market cap of $76.6 million and is part of the

health care

sector and


industry. Shares are down 76.5% year to date as of the close of trading on Thursday.

TheStreet Recommends

China-Biotics, Inc. engages in the research, development, production, marketing, and distribution of probiotics products in the People's Republic of China. Its products contain live microbial food supplements, which beneficially affect the host by improving its intestinal microbial balance. The company has a P/E ratio of 2.7, equal to the average drugs industry P/E ratio and below the S&P 500 P/E ratio of 17.7.

  • Practice your CHBT trading strategies and win cash in our stock game.

TheStreet Ratings rates China-biotics as a


. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures and growth in earnings per share. However, as a counter to these strengths, we also find weaknesses including weak operating cash flow and a generally disappointing performance in the stock itself. You can view the full

China-biotics Ratings Report


See all

52-week low stocks

or get investment ideas from our

investment research center